Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries-Reference-Cited by-同舟云学术

Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

Published:2018-04-02 Issue:3 Volume:181 Page:350-359
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Díez-Campelo María¹²^ORCID,Lorenzo Jose I.³,Itzykson Raphael⁴,Rojas Silvia M.¹,Berthon Céline⁵,Luño Elisa⁶,Beyne-Rauzy Odile⁷,Perez-Oteyza Jaime⁸,Vey Norbert⁹,Bargay Joan¹⁰,Park Sophie¹¹,Cedena Teresa¹²^ORCID,Bordessoule Dominique¹³,Muñoz Juan A.¹⁴,Gyan Emmanuel¹⁵,Such Esperanza³,Visanica Sorin¹⁶,López-Cadenas Félix¹,de Botton Stéphane¹⁷,Hernández-Rivas Jesús M.¹²,Ame Shanti¹⁸,Stamatoullas Aspasia¹⁹,Delaunay Jacques²⁰,Salanoubat Celia²¹,Isnard Françoise²²,Guieze Romain²³,Pérez Guallar Joan²⁴,Badiella Llorenc²⁴,Sanz Guillermo³,Cañizo Consuelo¹²,Fenaux Pierre⁴^ORCID

Affiliation:

1. Haematology, Hospital Universitario de Salamanca; Salamanca Spain

2. Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain

3. Haematology Department; Hospital Universitario y Politécnico La Fe; Valencia Spain

4. Service d'Hematologie; St Louis, assistance publique hôpitaux de Paris and Paris Diderot University; Paris France

5. Maladies du Sang; Hopital Huriez; CHRU de Lille; Lille France

6. Haematology; Hospital Universitario Central de Asturias; Oviedo Spain

7. Haematology; CHU Purpan; Toulouse France

8. Haematology; Hospital Sanchinarro Norte; Madrid Spain

9. Haematology department; Institut Paoli Calmettes; Marseille France

10. Hospital Sont Llatzer; Palma de Mallorca Spain

11. Haematology; Clinique Universitaire d′Hématologie; CHU de Grenoble; Grenoble France

12. Hospital 12 de Octubre; Madrid Spain

13. Unité de Recherche Clinique; Service d'Hématologie Clinique et Thérapie Cellulaire; Limoges France

14. Hospital Puerta del Mar; Cadiz Spain

15. Service d'hématologie et thérapie cellulaire; CHRU de Tours; Team 3 UMR CNRS 7292; Université François Rabelais; Tours France

16. Hématologie - Hôpital Bon Secours; Metz-Thionville; Thionville France

17. Hematologie; Institut Gustave Roussy; Villejuif France

18. Haematology Department; Hôpital Civil; Strasbourg France

19. Haematology Department; Centre Henri Becquerel; Rouen France

20. Haematology Department; CHU de Nantes; Nantes France

21. Hôpital de Corbeil; Corbeil France

22. Department of Haematology; Assistance Publique-Hopitaux de Paris (AP-HP) Saint-Antoine; Universite Pierre et Marie Curie; Paris France

23. Hematologie; CHU Estaing; Clermont-Ferrand France

24. Department of application statistics; Universidad Autónoma de Barcelona; Barcelona Spain

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15190/fullpdf

Reference25 articles.

1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry;Bernal;Leukemia,2015

2. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia;Cheson;Blood,2006

3. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome;Cordoba;Cancer,2012

4. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry;Dinmohamed;Leukemia,2015

5. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes;Fenaux;Leukemia Research,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH);Current Research in Translational Medicine;2023-10

2. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system;International Journal of Hematology;2023-06-28

3. Myelodysplastic syndromes;Nature Reviews Disease Primers;2022-11-17

4. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group;Cancers;2022-05-17

5. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine;Epigenomics;2021-07